Scroll To Top

Vaccine Vigil

Vaccine Vigil


The National Institutes of Health launched a Phase II clinical trial in October of HVTN 205, an experimental preventive HIV vaccine that uses synthetic genes from strains A, B, and C of the virus, which account for 85% of the world's HIV cases. __________ Merck announced plans in September to double the enrollment in its clinical trial of MRKAd5--a preventive and therapeutic experimental HIV vaccine--after early study data showed that the vaccine boosted participants' CD4 cells to 50 to 100 times their baseline number. The vaccine uses a common cold virus to deliver key HIV genes into the body to stimulate the immune system to attack HIV.

Out Subscription Lil Nas XAdvocateChannel promotion

From our Sponsors

Most Popular

Fifth Person Cured of HIV

Latest Stories